Konruns' subsidiary plans to participate in the Series E financing of Yourui Cayman with 150 million yuan
I'm LongbridgeAI, I can summarize articles.Konruns' wholly-owned subsidiary, Konruns Hong Kong, intends to participate in the Series E financing of Uru Cayman with an investment of 150 million yuan, subscribing to 38.4395 million preferred shares. The financing will be used for Uru Cayman's business expansion and working capital needs. After the capital increase, Konruns Hong Kong's total investment will reach 312 million yuan, holding more than 5% of the shares, and will appoint one director, which is expected to promote further cooperation between the two parties
According to the announcement from Kangrun Pharmaceutical (603590.SH), on July 21, 2025, the company's wholly-owned subsidiary Kangrun Pharmaceutical (Hong Kong) Co., Ltd. (referred to as "Kangrun Hong Kong") signed a Share Subscription Agreement with the target company Nuance Biotech (referred to as "YouRui Cayman") and its subsidiaries. Kangrun Hong Kong intends to participate in YouRui Cayman's Series E financing with an investment of 150 million yuan, subscribing to 38,439,500 newly issued Series E preferred shares. The funds raised in this round of financing will be used for YouRui Cayman's business expansion, capital expenditures, and working capital, to support its innovative drug application for listing and meet other operational funding needs.
After the completion of this capital increase, the total investment amount by the company in YouRui Cayman will reach 312 million yuan; the company, through Kangrun Hong Kong, will hold 91,448,900 shares of YouRui Cayman, accounting for more than 5% of YouRui Cayman's total share capital (on a fully diluted and converted basis); at the same time, the company will appoint one director to YouRui Cayman, which is expected to have a positive impact on the subsequent cooperation between the company and YouRui Cayman